# Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects

> **NCT00481065** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 405 (actual)

## Conditions studied

- Pandemic
- Avian Influenza

## Interventions

- **BIOLOGICAL:** MF59-eH5N1
- **BIOLOGICAL:** eTIV_a
- **BIOLOGICAL:** MF59-eH5N1 + eTIV_a

## Key facts

- **NCT ID:** NCT00481065
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2014-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481065, "Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00481065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*